Fuensanta Bellvís Bataller

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Fuensanta Bellvís Bataller

Blog

Last News

Meet Matthew Good, Quibim’s new CFO

Quibim partners with Highlight Therapeutics
to advance immunotherapy in melanoma

One year into the pandemic:
+ 7,000 studies and a pledge to continue the fight with AI

Quibim Receives FDA 510(k) Clearance for qp-Prostate, a New AI Solution for Prostate MRI Analysis

Subscribe

Fuensanta Bellvís Bataller

Blog

Last News

Meet Matthew Good, Quibim’s new CFO

Quibim partners with Highlight Therapeutics to advance immunotherapy in melanoma

One year into the pandemic: + 7,000 studies and a pledge to continue the fight with AI

Quibim Receives FDA 510(k) Clearance for qp-Prostate, a New AI Solution for Prostate MRI Analysis

Subscribe

Looking for a seamless AI solution for your radiology department?

Quibim partners with Highlight Therapeutics
to advance immunotherapy in melanoma

One year into the pandemic:
+ 7,000 studies and a pledge to continue the fight with AI